Purpose: Status Epilepticus (SE) is a common medical emergency carrying a high morbidity and mortality. Levetiracetam (LEV) is a novel anticonvulsant effective against varied seizures. Few prospective studies have addressed its use in SE. We aimed to examine the efficacy of intravenous LEV in controlling SE and cluster attacks of seizures (CS), in comparison with IV phenytoin (DPH), using a prospective, randomized study design. Method: Adult patients with SE or CS, following an initial dose of IV benzodiazepine to control ongoing seizure, were randomized to receive either medication. Rates of seizure control over 24 h, adverse effects and outcomes were compared. A logistic regression model was used to identify outcome predictors. Results: 52 patients with SE and 63 with CS received either LEV or DPH. In the SE group, LEV was effective in18/22(82%) and DPH in 22/30(73.3%) patients in controlling seizures. Among patients with CS, LEV was effective in 31/38(81.6%) and DPH in 20/25(80%). With the use of LEV, DPH or both, SE and CS were controlled among 92% and 96% of patients respectively. Adverse events included hypotension (in 2 on DPH) and transient agitation (2 on LEV). Conclusions: IV Levetiracetam controls status epilepticus or cluster seizures with an efficacy comparable to that of phenytoin. Use of these two agents consecutively may control >90% of all such conditions without resort to anaesthetic agents. Further studies should explore its efficacy in larger cohorts of epileptic emergencies.
Introduction
Status Epilepticus (SE) is a fairly common medical emergency and carries a high morbidity and mortality. Its incidence is estimated to be 9.9 to 41 per 100,000/year, with peaks in children and the elderly [1] . Generalized convulsive SE is the most common and dangerous type. Outcome depends mostly on age, etiology and the duration of SE before initiating effective treatment. Few parenteral medications are currently available for the effective management of SE [2] . Most evidence supports the use of an injectable benzodiazepine followed by a longer acting agent such as IV phenytoin, valproate or phenobarbital as treatment for SE [2] [3] [4] . However, refractoriness of seizures to these medication as well as significant adverse effects consequent to their use are well recognized limitations to current regimes for treating SE [3, 4] . In the recent past, a few intravenous agents with better safety profiles have become available: examples are sodium valproate, levetiracetam and lacosamide [4, 5] . Levetiracetam and Lacosamide, being fairly recent additions, have not been extensively studied [4] [5] [6] [7] [8] . Most reviews of SE recommend randomized studies for examining the efficacy of new AEDs.
Levetiracetam (LEV) has a novel mechanism of action: it binds to neuronal synaptic vesicle protein 2A and inhibits calcium release from intra-neuronal stores; this results in suppression of release of neurotransmitters [9] . It is one of the few anticonvulsants available in a parenteral formulation. LEV is well tolerated in healthy subjects, even when administered rapidly in high doses of up to 4000 mg/15 min [10] . LEV has several advantages: rapid efficacy in seizure control; good renal clearance; relative absence of drug interactions; absence of induction of hepatic enzymes; absence of respiratory depression or cardiac adverse effects; and compatibility with any IV diluent. The main adverse effects associated with LEV use are behavioral changes and sedation in small number of patients [10] . Relatively few studies have examined its efficacy in treating epileptic emergencies [9] [10] [11] [12] [13] [14] [15] . Two retrospective studies on SE involving 32 and 36 patients receiving LEV reported effective control of SE in about two thirds of the patients, with mild transient adverse effects [11, 12] . In a review of studies involving 498 patients with SE treated with LEV (including 215 with resistant SE), control rates of 45-100% (mean-70%) were reported. However, these were studies with varied designs, mostly including retrospective reviews [13] . Another review reported on 10 studies (334 patients) with LEV as the first AED for SE; seven were retrospective observational studies while only three were randomized. LEV was reported to be effective among 44-94% patients with SE among these studies [14] .
Aim
This study aimed to examine the efficacy of IV levetiracetam versus IV phenytoin, administered after an IV benzodiazepine (for an ongoing seizure) in controlling status epilepticus (SE) and cluster attacks of seizures (CS), using a prospective, open-label, randomized study design.
Patients and methods
Consecutive adult ( > 15 years age) patients presenting with SE or CS to our university-teaching hospital were recruited. SE is defined for the purpose of this study as a prolonged ( > 5 min) or recurrent generalized tonic-clonic seizure(s) with no regaining of consciousness between attacks, or partial seizures persisting for more than 10 mins [15] . Cluster attacks of seizures (CS) were defined as recurrent episodes of seizures À two or more over previous 24 h À (partial or generalized) with return of consciousness between episodes, with the last episode occurring within 2 h of evaluation. Patients with known allergy to drugs used, those requiring immediate neurosurgery, having hemodynamic compromise (systolic BP <100 mm Hg), serious arrhythmias (eg. heart rate <50/min, second or third degree heart block, runs of ventricular ectopics), pregnancy, cardiac failure or pulmonary edema, in pre-terminal states or having pseudo-seizures were excluded. Patients with subtle SE, defined as altered mental status without overt convulsions but with ongoing epileptiform activity noted on EEG, were also excluded.
Diagnosis of SE/CS was supported by a brief history and focused clinical and neurologic examination. Patients underwent investigations including full blood counts; serum biochemistry including glucose, electrolytes, renal function tests, calcium profile; and CT scan (or MRI) as appropriate to establish a diagnosis.
As this study proposed to treat patients with a potentially lifethreatening condition where the need for controlling ongoing seizures was of importance, no consent was obtained initially from the patient or care giver prior to initial AED administration; after stabilization, consent to continue with collection of data till discharge was obtained. Approval from the institutional Ethics and Medical Research committees for this study protocol was obtained. Additional supports for choosing such a consent protocol were the evidence of a relatively mild adverse event profile reported in the literature, empirical experience with LEV locally, and the practice of pragmatic use of an emergent medication in the context of equipoise of evidence favoring either agent noted in the literature 13 . An open-label design was chosen mainly to ensure patient safety. Patients observed to have ongoing seizures received IV benzodiazepine À lorazepam 4 mg or diazepam 5-10 mg over 2 min, for aborting the seizure. This was followed immediately (or as initial treatment for those without ongoing seizures) by LEV or DPH, with the choice determined based on computer-generated list of random numbers. The dosages used were:
IV phenytoin-20 mg/kg over 30 min-or IV levetiracetam-30 mg/kg over 30 min.
During infusion, close clinical, ECG and blood pressure monitoring were ensured. Following initial stabilization, the patients were managed in Emergency unit, High-Dependence Unit or ICU (as appropriate). Control of SE or CS was recognized by the cessation of seizures, improvement in mental status and nonrecurrence of seizures over the next 24 h. In case of recurrence of seizure up to 24 h from the initial AED, 10 mg/kg IV bolus of the same AED was administered; if seizure recurred even after this additional load, the alternative AED was administered in full dose, followed if necessary with an additional 10 mg/kg bolus. A patient not responding to both the AEDs was considered to have 'Resistant SE', was transferred to the ICU and treated with intravenous anaesthetic agents under EEG monitoring as appropriate. Patients were followed till discharge from hospital. The primary end point of the study was control of seizures with no recurrence over next 24 h. Secondary end points were occurrence of any adverse effect directly attributable to the administered AED (sedation, drowsiness, coma, change in behavior, rash, hypotension, arrhythmias, respiratory failure, etc); and outcome at hospital discharge graded on modified Rankin Score (mRS) Àdichotomized as: good outcome: 0-3 or poor outcome: 4-6.
All patients whose SE/CS was controlled with an AED received the corresponding AED as maintenance treatment: 300 mg/day for DPH 24 h after initial dose, or 1-1.5 gm bid of LEV, starting 12 h after first dose. Other AEDs used previously were continued as appropriate.
Analysis
Sample size estimates for a similar study design have been reported to be 500 patients for estimated AED efficacy rates of 50% with 10% group difference in proportions and 85% power 13 .
However, a convenience sample size of 100 patients was chosen for this study, based on number of cases treated at our center annually. Data are presented as frequencies (for categorical data) or means with standard deviation (for continuous data). Univariate analysis with suitable statistical techniques such as Chi square test, independent samples t test and estimation of relative risk and risk difference, were used to explore the above mentioned primary and secondary outcomes. Similar analysis for a combined group including both SE and CS was also performed. A multivariate analysis (backward conditional model) was performed to explore factors independently predicting outcome for each category (SE and CS) and for combined cohort. p < 0.05 was considered significant.
Results

Status Epilepticus
A total of 52 patients (M:F: 34:18; mean age: 37.8 AE 18 years) with SE were recruited. Demographics, cause of SE, clinical data and outcomes are summarized in Table 1 . The causes of SE included: cryptogenic epilepsy: 39 (56%); acute symptomatic epilepsy À 8 (15%) (including acute stroke-2, metabolic disorders-2, autoimmune encephalopathy-2, and one each with tumour and unknown cause); and remote symptomatic epilepsy-15 (29%) (including post-stroke epilepsy À3 and post-traumatic epilepsy À2, autoimmune/amyloid encephalopathy-2, Lafora disease À 3, and one each with Multiple sclerosis, progressive myoclonic epilepsy, brain tumour, CNS angiitis and neurocysticercosis). Among patients with long standing epilepsy, two thirds had SE likely due to non-compliance to medication. Fifty patients had generalized SE while two had partial SE. 15 patients (29%) required ICU management.
22 patients received LEV and 30 received DPH, following a bolus of IV benzodiazepine as required. Age, gender, cause of SE, ICU admission rates, SOFA (Sequential Organ Specific Assessment) scores (a summary score for metabolic derangements), abnormal imaging rates and initial use of benzodiazepine were similar in both groups (Table 1) . LEV was effective in controlling SE in 18/22 (82%) while DPH was effective among 21/30 (70%) (p = 0.33). 30 patients received LEV as first or second agent for SE; of these, 23/31 (76.6%) were controlled. Similarly, 32 patients received DPH as first or second AED and 22/32 (68.8%) were controlled. When sequentially used, the two anticonvulsants were effective in controlling SE among 48/52 (92.3%) patients, with only four being resistant to both the agents.
Rates of adverse events were low. Transient hypotension (responding to IV saline) was observed in two patients receiving IV DPH; one patient on LEV had transient thrombocytopenia which normalized over three days, while another had transient agitation and anxiety. Poor outcome (mRS 4-6) at hospital discharge was lower among patients in LEV group (48% vs DPH À 59%; p = 0.29). Of the 15 patients treated in the ICU, 8 improved while 7 had poor outcome. Overall five patients died due to underlying conditions: two in LEV group (one each with Lafora disease and epilepsy following recurrent disabling stroke) and three in DPH group (one each with mental retardation and epilepsy; CNS angiitis with progressive encephalopathy; and autoimmune encephalopathy with super-refractory SE). All five patients expired after being treated in the hospital for several days to few weeks, with none having had adverse reaction to the anticonvulsant medications used initially. On univariate analysis, cause of SE (epilepsy vs other causes, p = 0.011), younger age (p = 0.002) and higher serum albumin (p < 0.001) were associated with good outcome. Multiple logistic regression analysis revealed only serum albumin to be independently predictive of outcome at discharge (p = 0.004; Exp B = 071 95% CI: 0.56-0.89).
Cluster Seizures
Sixty three patients with cluster seizures (CS) were included (M:F:44:19; Age: 39.3 AE 20 years). The causes of CS included cryptogenic epilepsy À40; acute symptomatic epilepsy À11 (head injury À3; eclampsia-2; one each with: glioma, intracerebral hemorrhage, cerebral venous thrombosis, alcohol, sepsis, limbic encephalitis); or remote symptomatic epilepsy À12 (post-stroke epilepsy-10, SLE-1, Sickle cell disease-1). 42 (67%) presented with recurrent generalized seizures while 21 (33%) had focal seizures of different varieties. Six patients had metabolic derangements resulting in SOFA scores of 4-6 (overall suggestive of mild to moderate disturbance). Most patients remained conscious and only four patients (two in each group) required ICU care, though none required intubation.
Of the 63 patients, 38 received LEV and 25-DPH (Table 2) . While age, gender, etiology and type of seizures and imaging profiles were comparable, a higher proportion of patients in DPH group required initial IV benzodiazepine as compared to the LEV group (76% vs 40%; p = 0.004). LEV was effective as the first AED among 31/38 patients (81.6%) while DPH was effective among 20/25 (80%). When used as either first or second AED, LEV and DPH were effective among 36/43 (83.7%) and 22/29 (75.9%) of the cases respectively. With the use of one or both these AEDs, CS were controlled in 61/63 (96.8%) patients; only two patients were resistant to both AEDs.
Adverse event rates were low, with two patients receiving DPH experiencing local pain, while transient agitation was noted in one patient in LEV group. Good outcome rates were higher in the LEV group compared to DPH (79% vs 70%); however, these differences were only marginally significant (p = 0.049). One patient with a progressive encephalopathy of suspected autoimmune etiology and sepsis who received DPH for cluster seizures died after prolonged ICU care. On univariate analysis, age, plasma albumin, total proteins and anticonvulsant used (favoring LEV) were significantly associated with outcome status at discharge (p > 0.05). Multiple logistic regression analysis revealed plasma protein level (p = 0.03, Exp B: 0.9; 95% CI: 0.83-0.99) and anticonvulsant used (p = 0.004; ExpB:0.018; 95% CI: 0.001-0.27) to be factors independently predicting outcome. Overall, among the 115 patients studied including both SE and CS, randomization failied in about a third of the patients (10 in SE, 22 in CS). The reasons for this were either that the patient was already on an adequate dose of the AED assigned by randomization process, was known to have failed to respond to it earlier or was considered unsafe to receive it (eg. hypotension or arrhythmias in patients assigned to DPH); in these contexts, the AED (LEV or DPH) decided appropriate by the treating physician was administered. On analyzing the efficacy of AEDs in controlling the seizures after removing these cases, the results were similar to those observed for the whole groups: In SE group, first AED received was effective among 14/17 (82.3%) treated with LEV vs 19/25 (76%) treated with DPH (p = 0.62). In CS group, response rates were 21/26 (80.8%) vs 11/15 (73.3%) respectively (p = 0.58).
Discussion
Epileptic emergencies are managed in emergent settings with many issues influencing therapeutic decisions, including AED efficacy and adverse effect profiles. This study compared the efficacy of LEV versus DPH in patients with SE or CS using a prospective, open label design. The results support the overall conclusion that LEV is comparable in its efficacy to DPH for treating SE or CS. The efficacy of LEV was similar in both the types of epileptic emergencies. In the CS group, efficacy of LEV remained comparable to DPH despite the higher incidence of use of initial benzodiazepine in DPH cohort. The overall rates of adverse events were low and mild in severity, suggesting a fairly safe profile for LEV in actual clinical context. Also, with the sequential use of these two AEDs, a majority of the cases (92-97%) could be controlled without recourse to anesthetic agents.
Our results among patients with SE appear to be comparable to those in similar earlier studies. A prospective, open label study comparing efficacy of LEV and DPH among 44 patients reported control of SE in 59.1% receiving LEV and 68.2% receiving DPH (p = 0.53) [16] . A second prospective, randomized study by Mundlamuri et al compared LEV with DPH and sodium valproate among patients with SE (n = 50 in each arm), administered after initial IV lorazepam in all patients. They observed control of SE in 78%, 68% and 68% of patients with LEV, DPH and valproate respectively [17] . This study also reported achieving control of SE among 94% of patient with the sequential use of these three AEDs, similar to our observations. The overall dose of LEV used in these studies for SE was similar to that used in our study, viz $30 mg/kg (actual mean dose of LEV used in present study was: 1.37 AE 0.5 gm; and DPH 1 AE 0.27 gm).Two other prospective, randomized studies reported control rates for LEV (73.2% and 75.6%) in SE similar to ours; however the control medication was different (valproate or lorazepam) [18, 19] . Recommendations for the use of higher doses À of 2-4 g bolus À exist in the literature [20] ; however, based on our observations of comparable efficacy with other studies, such high doses may not be warranted, at least in our population. The higher limit of LEV dose for epileptic emergencies in practice may need further study in the above context. The safety profile of LEV is noted to be favorable in these as well as earlier studies, with no mention of hemodynamic changes or respiratory compromise. Transient behavioral change or psychosis has been reported in a few studies, as was observed in two of our patients.
Very few studies address the efficacy of AEDs in patients with CS as a group. We chose to examine this group specifically as they often progress to SE if not treated promptly. A study in children reported that LEV was effective in terminating 'acute repetitive seizures' among 62% of 39 patients treated, compared to 80% efficacy in our study [20] .
In this study, we examined overall factors influencing outcome and observed AED used (LEV) was a factor independently influencing outcome in the CS group, in addition to others such as cause of CS, duration of seizures, age, etc. The relatively safer adverse effect profile of LEV, as compared to DPH À particularly when used in sick patients, may possibly have contributed to this trend.
The strengths of the current study are its prospective design; inclusion of CS as a study arm; inclusion of cases with varied causes of SE or CS in the context of a general Emergency department; and exploring factors influencing overall outcome. Our study has several limitations. A major limitation was the failure of randomization process in about a third of the cases, mainly due to the urgency of interventions required. During actual patient encounters, a patient on LEV or DPH in adequate doses prior to SE or CS who was known to have failed to respond to it earlier, or was deemed unsafe to receive it, received the alternative AED rather than according to the randomization guided choice. This limitation would be difficult to overcome in similar studies if the focus is on better patient outcomes rather than study design. A second limitation was the choice of an earlier definition of SE for this study [21] . This study was initiated prior to the publication of the new definition of SE [22] ; however, on comparing the two, none of our cases which would merit treatment according to either definition appear to have been excluded. Other limitations include small number of patients; varied underlying conditions and long duration of SE in several cases. In summary, this prospective open label study observed comparable efficacy of LEV and DPH in the management of SE and CS. LEV was associated with less severe adverse events and possibly, better outcome at discharge. We conclude that LEV is effective and fairly safe for use among patients with SE/CS. Further studies are indeed essential to validate these observations among larger number of patients, preferably stratified by etiology or severity of the underlying conditions. A model of sequential use of selected AEDs may also be explored so as to develop safer and more effective treatment protocols for this life threatening condition.
Division of labour
Dr. Arunoday R Gujjar (PI) Overall development of the research design, supervising data management and analysis of results. Share in supervision, sourcing patients; recruiting into study and conduct of the study .
Dr. Abdullah Al-Asmi (Co-PI): Development of research design, supervision of study, sourcing patients; recruiting into study, patient management.
Dr. R. Nandagopal: Sourcing patients; recruiting into study, management of patients; maintaining case records.
Dr. PC Jacob, Dr.Khalfan Al-Amrani, Dr.Abdulhakeem Al Hashim: Sourcing patients; recruiting into study, management of patients.
Dr. Shyam S Ganguly: Development of study design, monitoring progress, analysis.
